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Key questions
What is already known about this subject?
 ► Very little is known on the subject of quality of life 
(QOL) and coronary endothelial function.
 ► No studies to our knowledge have specifically ad-
dressed the effects of diagnosis and treatment of 
coronary endothelial dysfunction on long-term QOL.
What does this study add?
 ► In this manuscript we report the results of the im-
pact of diagnosis and treatment of patients with 
coronary microvascular endothelial dysfunction and 
non-obstructive coronary artery disease (CAD) on 
long-term QOL.
 ► These results demonstrate that among patients with 
chest pain and normal coronaries, the diagnosis 
and treatment of coronary microvascular endothe-
lial dysfunction in those with angina pectoris and 
non-obstructive CAD are associated with better QOL 
compared with patients with normal endothelial 
function.
How might this impact on clinical practice?
 ► The findings bring novel information to support 
the use of coronary endothelial function testing by 
skilled operators in the diagnosis of microvascular 
disease in patients with atypical chest pain that is 
not due to obstructive disease.
 ► The results of the study suggest that the diagnosis 
and subsequent treatment of patients found to have 
microvascular disease may lead to an improvement 
in QOL.
AbstrAct
Aim Angina pectoris in the absence of obstructive 
coronary artery disease (CAD) is common and is 
associated with poor quality of life (QOL). Coronary 
microvascular endothelial dysfunction is associated with 
myocardial ischaemia and is a common cause of angina. 
We hypothesise that evaluation of coronary endothelial 
function, its diagnosis and treatment will favourably 
impact QOL in patients with angina symptoms and non-
obstructive CAD.
Methods and results Follow-up was done on 457 
patients with chest pain and non-obstructive coronary 
arteries who had undergone coronary vascular reactivity 
evaluation by administration of intracoronary acetylcholine 
at the time of diagnostic study. After a mean follow-up 
of 8.4±4.7 years, QOL was assessed by administration 
of the SF-36 QOL survey. Patients diagnosed and 
treated for microvascular endothelial dysfunction had a 
higher (better) overall mental composite score (44.8 vs 
40.9, p=0.036) and mental health score (44.2 vs 40.7, 
p=0.047), and a trend towards higher vitality scores (39.1 
vs 35.9, p=0.053) and role emotional scores (43.6 vs 40.4, 
p=0.073), compared with patients with normal endothelial 
function.
Conclusion Among patients with chest pain and 
normal coronaries, diagnosis and treatment of coronary 
microvascular endothelial dysfunction in those with 
angina pectoris and non-obstructive CAD are associated 
with better QOL compared with patients with normal 
endothelial function.
IntroduCtIon
Angina pectoris with normal coronaries is 
a common phenomenon occurring in over 
60% of patients undergoing coronary angi-
ography in the USA.1 Patients with persistent 
chest pain and normal or non-obstructive 
coronary angiograms have poor quality of 
life (QOL) and consume large amounts of 
healthcare resources due to repeat evalua-
tions for diagnostic and therapeutic uncer-
tainty.2 3 Coronary microvascular endothelial 
dysfunction is associated with myocardial 
ischaemia4 and cardiovascular events,5–7 and 
can be an important mechanism for persis-
tent chest pain in these patients.8
The identification and treatment of coro-
nary microvascular endothelial dysfunction as 
a cause of angina in these patients may poten-
tially modify their disease. Furthermore, 
recent studies have shown that reversal of 
endothelial dysfunction is associated with an 
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improvement in cardiovascular prognosis.9 10 The effect 
of diagnosis and treatment of microvascular endothelial 
dysfunction on long-term QOL in patients with angina 
and normal angiograms has however not been studied.
Therefore, the aim of this study was to evaluate the 
impact of diagnosis and treatment of patients with coro-
nary microvascular endothelial dysfunction and non-ob-
structive coronary artery disease (CAD) on long-term 
QOL.
MetHods
study design
This study is a prospective cohort study in a single centre.
study population
The study group consisted of 457 patients with chest 
pain who were referred to the cardiac catheterisation 
laboratory for evaluation of CAD, found to have non-ob-
structive disease, and had comprehensive coronary phys-
iology study including assessment of endothelial func-
tion and non-endothelium-independent coronary flow 
reserve.11–14
Exclusion criteria included significant coronary artery 
stenosis (>40%), ejection fraction <45%, unstable angina, 
previous myocardial infarction, use of radiographic 
contrast agents within 12 hours, significant systemic 
disease and pregnancy. Patients who did not return a 
follow-up questionnaire were excluded.
study protocol
Medications that may affect cardiovascular haemody-
namics were discontinued for at least 48 hours before 
the study. At baseline, diagnostic coronary angiography 
and determination of endothelium-dependent changes 
in Coronary Blood Flow (CBF) and endothelium-inde-
pendent coronary flow reserve were performed as previ-
ously described.4 15 A Doppler guidewire (0.014-inch 
diameter, FloWire, Volcano) within a 2.2 F coronary 
infusion catheter (Ultrafuse, SciMed Life System) was 
advanced and positioned in the middle portion of the 
left anterior descending coronary artery (LAD). Intracor-
onary bolus injections of incremental doses (18–72 µg) 
of adenosine (Fujisawa), an endothelium-independent 
vasodilator (primarily of the microcirculation),16 were 
administered into the guiding catheter until maximal 
hyperaemia was achieved.
Assessment of the endothelium-dependent changes 
in CBF was performed by selective infusion of acetylcho-
line (ACh) into the LAD. ACh (Iolab Pharmaceuticals) 
10−6, 10−5 and 10−4 mol/L were infused at 1 mL/min for 
3 min.4 17 Haemodynamic data (heart rate and mean 
arterial pressure), Doppler measurements and coronary 
angiography were obtained after each infusion. Endothe-
lium-independent epicardial vasodilation was assessed 
with an intracoronary bolus injection of nitroglycerin 
(200 µg, Abbott Laboratories).18
Microvascular endothelial function
Doppler flow velocity spectra were analysed online 
to determine the time-averaged peak velocity. Volu-
metric CBF was determined from the following rela-
tion: CBF=cross-sectional area × average peak velocity × 
0.5.19 Endothelium-dependent microvascular function 
was calculated as % ∆ CBF in response to ACh as previ-
ously described.20 As previously reported microvascular 
endothelial dysfunction was defined as ≤50% increase in 
CBF in response to the maximal dose of ACh compared 
with baseline CBF.6 Patients were divided into two groups 
based on the presence of microvascular endothelial 
dysfunction.
epicardial vascular function testing
Coronary artery diameter was analysed by quantitative 
coronary angiograms from digital images using a modi-
fied, previously described technique from this institu-
tion.4 13 The LAD was divided into proximal, middle and 
distal segments. For each segment, the measurements 
were performed in the region where the greatest change 
had occurred during the ACh infusion. An angiographi-
cally smooth segment of the proximal, middle and distal 
LAD, free of any overlapping branch vessels, was identi-
fied in each patient and served as the reference diameter 
for the calculation of diameter stenosis. End-diastolic 
cine frames that best showed the segment were selected 
and calibration of the video and cine images was done, 
identifying the diameter of the guide catheter. Quantita-
tive measurements of the coronary arteries were obtained 
using a computer-based image analysis system. Segment 
diameters were determined at baseline and after both 
ACh and nitroglycerin administration. The proximal 
segment was not exposed to ACh and thus served a 
control segment.
Epicardial coronary endothelial dysfunction was 
defined as a decrease or no increase in coronary artery 
diameter in response to the maximal dose of ACh 
compared with baseline.21
Follow-up
After a mean follow-up of 8.4±4.7 years, QOL was assessed 
by administration of Short Form (36) Health (SF-36) 
survey.22 Patients were contacted by mail and the SF-36 
survey sent to them.
survey instrument
The SF-36 survey is a well-validated, multipurpose, short-
form health survey with 36 questions. It is an 8-scale 
profile of functional health, well-being and mental health 
that forms a generic measure of participants’ perception 
of their health status and their mental and physical well-
being (figure 1).22–25
statistical analysis
Data are displayed as mean±SD or count and percentage 
as appropriate. Variables with heavily skewed distribution 
are reported as medians with first and third quartiles 
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Figure 1 Summary of the measures and scales of the quality of life SF-36 survey.
in parenthesis. Analysis to compare different demo-
graphic and baseline clinical data between the groups 
was performed using analysis of variance for continuous 
data and the Pearson’s χ2 test for categorical data. Base-
line data for the CBF, CFR and coronary artery diameter 
were compared using a rank-sum test. Statistical analyses 
were performed using JMP V.14 (SAS Institute, Cary, NC, 
1989–2018).
Quality of life
The responses to the SF-36 items for the 8-scale SF-36 scale 
were scored using the publisher’s normative methods, 
which in turn generated the summary physical and mental 
components scores. All of these scores are standardised 
such that in a normal age-matched and sex-matched 
reference population the mean score is equal to 50 and 
the SD of the scores is equal to 10. Patients who have 
SF-36 scores greater than 50 report better health-related 
QOL than the normal population, and scores less than 50 
indicate poorer QOL. Differences between the groups in 
the QOL analysis were compared using Student’s t-test. 
Multiple linear regression was used to estimate the differ-
ence in QOL adjusted for other covariates. The model 
was adjusted for covariates which included the baseline 
characteristics (reported in table 1) as well as the medi-
cation use at baseline (reported in table 2). All statistical 
tests were two-sided, and a p<0.05 was considered to be 
statistically significant.
results
Therefore 457 patients were included in the study, of 
whom 258 (56%) had microvascular endothelial dysfunc-
tion. There were 313 women (68%), and the mean age of 
the study population was 52 years (range, 17–78 years). 
Most patients (92%) had >1 risk factor for CAD. The 
mean duration of follow-up was 8.4±4.7 years.
Baseline characteristics
Patients with microvascular dysfunction were slightly 
older compared with patients with normal endothelial 
function (mean age 54 vs 51, p=0.028) and had a lower 
smoking rate. The groups were otherwise well matched at 
baseline with regard to gender, race, other cardiovascular 
risk factors and inflammatory marker (table 1).
Medications at baseline
Patients with microvascular dysfunction had a higher rate 
of lipid-lowering drugs use (43% vs 33%, p=0.032) and a 
lower rate of aspirin use (43% vs 52%, p=0.06) (did not 
reach statistical significance) compared with patients with 
normal microvascular function. The two groups matched 
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Table 1 Baseline patient characteristics, by microvascular function
Variable
Normal microvascular 
endothelial function
(n=199)
Microvascular endothelial 
dysfunction
(n=258) P value
Age, years 51.9±12.3 54.4±11.6 0.03
Men, n (%) 66 (33) 78 (30) 0.50
Vascular disease, n (%) 16 (8) 22 (9) 5
Hypertension, n (%) 76 (38) 109 (43) 0.34
Diabetes, n (%) 15 (8) 24 (9) 0.50
Hyperlipidaemia, n (%) 116 (59) 148 (58) 0.78
Depression, n (%) 60 (31) 61 (24) 0.13
Smoking status, n (%) 0.03
  Never smoked 98 (49) 150 (58)
  Former smoker 77 (39) 93 (36)
  Current smoker 23 (12) 15 (6)
Height, cm 168.6±10.0 167.6±9.2 0.29
Weight, kg 79.8±19.1 80.6±20.3 0.68
Body mass index 28.0±6.1 28.5±6.3 0.38
Haemoglobin, g/L 135±13 135±13 0.60
Glucose, mg/dL, median (Q1, Q3) 95.0 (88.0, 105.0) 96.0 (89.0, 104.0) 0.49
Creatinine, mg/dL, median (Q1, Q3) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1) 0.58
Total cholesterol, mg/dL 194.5±47.1 191.4±43.4 0.49
LDL-C, mg/dL 111.2±39.4 110.1±38.1 0.77
HDL-C, mg/dL 54.4±16.8 54.4±16.1 1.00
Triglycerides, mg/dL, median (Q1, Q3) 121.0 (85.0, 176.5) 113.5 (81.0, 171.0) 0.32
hsCRP, mg/L, median (Q1, Q3) 0.5 (0.2, 1.6) 0.6 (0.2, 1.9) 0.65
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C reactive 
protein.
Table 2 Medication use, by microvascular function
Variable
Normal microvascular 
endothelial function
(n=199)
Microvascular endothelial 
dysfunction
(n=258) P value
Aspirin use, n (%) 85 (43) 133 (52) 0.06
ACE inhibitor use, n (%) 33 (17) 40 (16) 0.75
Beta-blocker use, n (%) 52 (26) 81 (31) 0.22
Calcium channel blocker use, n (%) 68 (34) 88 (34) 0.96
Lipid-lowering drug use, n (%) 66 (33) 111 (43) 0.03
Antiarrhythmic use, n (%) 14 (7) 20 (8) 0.77
Anticoagulant use, n (%) 18 (9) 34 (13) 0.18
Antihypertensive use, n (%) 41 (21) 60 (23) 0.50
Nitrates use, n (%) 67 (34) 93 (36) 0.60
Diuretics use, n (%) 33 (17) 45 (17) 0.81
Oral hypoglycaemic use, n (%) 7 (4) 14 (5) 0.33
Insulin use, n (%) 5 (3) 8 (3) 0.71
well on the frequency of use of other cardiac medications 
including beta-blockers, ACE inhibitors use and calcium 
channel blockers (table 2).
Microvascular and epicardial endothelial function
Patients in the microvascular coronary dysfunction group 
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Table 3 Endothelial function and Short Form (36) Health (SF-36) survey results, by microvascular function
Variable
Normal microvascular
endothelial function
(n=199)
Microvascular
endothelial dysfunction
(n=258) P value
% change CBF (ACh) 132.9±80.0 −12.0±35.7 <0.001
% change CAD (ACh) −3.8±15.2 −25.7±20.5 <0.001
% change CAD ≤−20%, n (%) 32 (16) 149 (58) <0.001
Coronary flow reserve 2.93±0.74 2.76±0.67 0.01
Months from study to survey, mean±Standard Deviation 85.5±55.4 82.7±48.2 0.27
SF-36 Std. Physical component score, mean±SD 37.0±19.5 38.7±17.7 0.33
SF-36 Std. Mental component score, mean±SD 40.1±20.1 43.9±18.1 0.04
Physical functioning, age-adjusted and sex-adjusted, mean±SD 39.5±20.4 41.9±18.3 0.19
Role physical, age-adjusted and sex-adjusted, mean±SD 37.0±19.4 39.2±17.6 0.20
Body pain, age-adjusted and sex-adjusted, mean±SD 37.6±18.2 39.3±16.7 0.28
General health, age-adjusted and sex-adjusted, mean±SD 37.8±19.6 40.2±17.7 0.16
Vitality, age-adjusted and sex-adjusted, mean±SD 36.0±17.9 39.1±17.0 0.05
Social function, age-adjusted and sex-adjusted, mean±SD 39.3±20 42.2±18.3 0.11
Role emotional, age-adjusted and sex-adjusted, mean±SD 40.4±20.0 43.6±18.5 0.07
Mental health, age-adjusted and sex-adjusted, mean±SD 40.7±20.0 44.2±17.7 0.04
ACh, acetylcholine; CAD, coronary artery disease.
had a lower mean per cent change in CAD after maximal 
dose of ACh from baseline (greater vasoconstriction) 
compared with patients with normal microvascular 
endothelial function (−25.7% vs −3.8%, p<0.001). There 
was also a higher percentage of patients with epicardial 
endothelial dysfunction (58% vs 16%, p<0.001) in the 
microvascular coronary dysfunction group compared 
with the group with normal microvascular endothelial 
function.
Quality of life
At the time they were surveyed, patients who were diag-
nosed and treated for microvascular endothelial dysfunc-
tion experienced higher overall mental composite score 
(44.8 vs 40.9, p=0.036) and mental health (44.2 vs 40.7, 
p=0.047), and a trend towards higher vitality (39.1 vs 35.9, 
p=0.053) and role emotional (43.6 vs 40.4, p=0.073), 
compared with patients with normal endothelial function 
(table 3 and figure 2).
subgroup analysis of women
On subgroup analysis, women with microvascular 
endothelial dysfunction had similar baseline characteris-
tics, frequency of cardiovascular risk factors, inflammatory 
markers and use of cardiovascular medication compared 
with women with normal microvascular endothelial func-
tion.
On QOL analysis women diagnosed and treated for 
microvascular endothelial dysfunction had a higher phys-
ical function (44.5 vs 40.4, p=0.039), general health (43.4 
vs 38.7, p=0.016) and vitality (42.1 vs 37.3, p=0.008), and 
a trend towards higher overall mental composite score 
(46.8 vs 43.4, p=0.08), overall physical composite score 
(41.1 vs 37.3, p=0.05), role emotional (46.5 vs 43.2, 
p=0.09), social function (44.8 vs 41.4, p=0.08) and role 
physical (42.1 vs 38.9, p=0.09), compared with women 
with normal endothelial function (table 4 and figure 3).
dIsCussIon
The current study demonstrated that among patients with 
chest pain and non-obstructive CAD, QOL with respect to 
measures of mental well-being during long-term follow-up 
is better in those patients who were assessed, diagnosed 
and received treatment for microvascular endothelial 
dysfunction compared with those who are found to have 
normal endothelial function. The current study suggests 
that assessment and treatment of microvascular angina 
may improve their QOL.
Patients with chest pain and non-obstructive CAD have 
been shown to have high morbidity and mortality than 
previously thought.26 27 These patients constitute a large 
percentage (up to 50%) of patients who undergo coro-
nary angiography studies for suspected myocardial isch-
aemia.28 These patients face diagnostic uncertainty and 
are high users of healthcare resources,26 29 30 due to the 
perceived need for frequent hospitalisation and multiple 
angiograms.31 They also have poor QOL, functional 
disability and limitations in activities of daily living.26 32 33
The aetiologies for chronic chest pain encompass 
a wide array of potential diagnoses, including cardiac 
and non-cardiac causes. Recent evidence suggests isch-
aemia due to coronary microvascular or macrovascular 
endothelial dysfunction34–37 may play a role, especially in 
women.28 37–40 Furthermore, the presence of microvas-
cular dysfunction is associated with adverse cardiovascular 
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Figure 2 Short Form (36) Health (SF-36) survey mental composite score, vitality and mental health in patients with 
microvascular endothelial dysfunction compared with patients with normal microvascular functions.
Table 4 Women and SF-36 results by microvascular function
Variable
Normal microvascular
endothelial function
(n=119)
Microvascular
endothelial dysfunction
(n=194) P value
% chg CBF 138.5±84.6 −2.1±47.1 <0.001
% chg CBF ≤50%, n (%) 0 (0) 180 (93) <0.001
% chg CAD 0.3±12.4 −24.4±18.3 <0.001
%chg. CAD ≤ −20%, n (%) 0 (0) 112 (58) <0.001
Months from ACh study to survey, mean±SD 84.3±56.9 82.7±48.3 0.580
SF-36 Std. Physical component score, mean±SD 37.4±18.4 41.1±15.8 0.05
SF-36 Std. Mental component score, mean±SD 43.4±18.9 46.8±15.4 0.08
Physical functioning, age-adjusted and sex-adjusted, mean±SD 40.4±18.8 44.5±16.0 0.05
Role physical, age-adjusted and sex-adjusted, mean±SD 38.9±18.2 42.1±15.5 0.09
Body pain, age-adjusted and sex-adjusted, mean±SD 38.8±17.3 41.3±14.8 0.16
General health, age-adjusted and sex-adjusted, mean±SD 38.7±18.6 43.4±15.5 0.02
Vitality, age-adjusted and sex-adjusted, mean±SD 37.3±16.8 42.1±14.8 0.01
Social function, age-adjusted and sex-adjusted, mean±SD 41.4±18.8 44.8±16.2 0.09
Role emotional, age-adjusted and sex-adjusted, mean±SD 43.2±18.5 46.5±15.6 0.09
Mental health, age-adjusted and sex-adjusted, mean±SD 43.9±18.8 47.0±15.1 0.11
ACh, acetylcholine; CAD, coronary artery disease.
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Figure 3 SF-36 physical functioning, vitality and general health in women with microvascular endothelial dysfunction 
compared with women with normal microvascular functions.
events and its treatment may lead to improved prog-
nosis.4 The need for proper diagnosis of chest pain in 
these patients is underscored by the recent guidelines 
and endorsement by the European Society of Cardiology. 
To our knowledge there are no studies in patients with 
chest pain showing the effect of diagnosis and treatment 
of microvascular endothelial dysfunction on QOL.
Our finding of higher QOL scores in patients with 
microvascular endothelial dysfunction who were on 
treatment compared with patients with normal endo-
thelial function may seem paradoxical. Previous studies 
have however found similar results. In one study women 
with chest pain and myocardial ischaemia had a higher 
QOL compared with women without.41 There are several 
potential mechanisms for this observation. First, lack of 
diagnosis for chest pain is a source of frustration for both 
the physician and the patient. Conversely, establishment 
of a diagnosis may alleviate anxiety for the patients, which 
would lead to improvement in the measures within the 
mental domains of QOL. Similar observations have also 
been made in patients admitted to hospitals for eval-
uation of suspected myocardial infarction. Patients in 
whom acute myocardial infarction was not confirmed 
reported more cardiovascular symptoms of chest pain, 
dyspnoea and palpitations, as well as more psychosomatic 
and psychological parameters, at 1 year compared with 
patients diagnosed with acute myocardial infarctions.42 
Furthermore patients with unstable angina pectoris are 
likely to experience poorer QOL following an acute 
hospitalisation than patients with other types of acute 
coronary syndrome.43 Second, the treatment of micro-
vascular dysfunction may relieve their symptoms, which 
may improve QOL. Previous studies have shown that 
treatment of angina is associated with improvement in 
physical, mental and social domains of QOL.44 Third, the 
paradoxical finding of better QOL in women with isch-
aemia compared with those without ischaemia41 45 may 
also in part explain our finding. Patients able to exercise 
to a sufficient workload to elicit an ischaemic response 
may have better QOL because they are less functionally 
impaired.41 The mechanism is thought to be due to less 
functional impairment in women with myocardial isch-
aemia compared with women without myocardial isch-
aemia. We have previously shown that microvascular 
coronary disease is associated with myocardial isch-
aemia in patients with non-obstructive coronary disease.4 
Although we did not specifically measure the exercise 
tolerance of our patients, it may be speculated that a 
similar mechanism may play a role in patients with chest 
pain and impaired microvascular function.
Persistent chest pain in the absence of coronary disease 
is more prevalent in women.46 47 Indeed, we found in 
our study a higher percentage of women having micro-
vascular endothelial dysfunction compared with men. In 
a subgroup analysis, the differences in QOL were more 
marked among women. We speculate that microvascular 
disease is thus more prevalent women, and its diagnosis 
and treatment may have greater benefit compared with 
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men. The current study further supports the notion that 
coronary microvascular dysfunction is one of the main 
mechanisms of chest pain in women.
limitations
There are several limitations to be mentioned. No base-
line QOL scores were obtained. Although the character-
istics of the two groups were similar at baseline, including 
cardiovascular risk factors and medication use, we do not 
have baseline QOL data for comparison. This precludes 
stronger inference about the cause and effect of any find-
ings. In addition there was no standardised treatment 
protocol for patients with microvascular disease, and the 
attending clinician determined the treatment based on 
the patient’s risk factors. We thus cannot draw definite 
conclusion on the effect of a specific treatment on QOL. 
In addition, we were unable to ascertain the medication 
use at follow-up and verify it with medical records because 
many of the patients did not follow up in our institution.
Our study was not designed to measure healthcare 
utilisation and functional status or to do cost analysis of 
potential healthcare saving of diagnosis and treatment 
of microvascular disease in patients with chest pain. This 
would have provided more outcome benefits, which 
could potentially be linked to improved QOL.
ConClusIons
Among patients with chest pain and non-obstructive CAD 
or normal coronary arteries, it is suggested that the diag-
nosis and subsequent treatment of patients found to have 
microvascular disease may lead to an improvement in 
QOL. These results support the use of coronary endothe-
lial function testing by skilled operators in the diagnosis 
of microvascular disease in patients with atypical chest 
pain that is not due to obstructive CAD.
Contributors The authors of the paper take full responsibility.
Funding The study was supported by grants from the NIH (NIH K24 HL-69840, 
NIH R01 HL-63911, HL-77131, HL 92954, HL 085307, DK 73608) and the Mayo 
Foundation.
Competing interests None declared.
Patient consent for publication Obtained.
ethics approval The Mayo Clinic Institutional Review Board approved the study.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement No additional data are available.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
RefeRences
 1. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective 
coronary angiography. N Engl J Med 2010;362:886–95.
 2. Bairey Merz CN, Shaw LJ. Stable angina in women: lessons from 
the national heart, lung and blood Institute-sponsored womenʼs 
ischemia syndrome evaluation. J Cardiovasc Med 2011;12:85–7.
 3. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the 
NHLBI-Sponsored women's ischemia syndrome evaluation (wise) 
study: part I: gender differences in traditional and novel risk factors, 
symptom evaluation, and gender-optimized diagnostic strategies. J 
Am Coll Cardiol 2006;47–S4–20.
 4. Hasdai D, Gibbons RJ, Holmes DR, et al. Coronary endothelial 
dysfunction in humans is associated with myocardial perfusion 
defects. Circulation 1997;96:3390–5.
 5. Lerman A, Zeiher AM. Endothelial function: cardiac events. 
Circulation 2005;111:363–8.
 6. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up 
of patients with mild coronary artery disease and endothelial 
dysfunction. Circulation 2000;101:948–54.
 7. Jespersen L, Hvelplund A, Abildstrøm SZ, et al. Stable angina 
pectoris with no obstructive coronary artery disease is associated 
with increased risks of major adverse cardiovascular events. Eur 
Heart J 2012;33:734–44.
 8. Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain 
predicts cardiovascular events in women without obstructive 
coronary artery disease: results from the NIH-NHLBI-sponsored 
women's ischaemia syndrome evaluation (wise) study. Eur Heart J 
2006;27:1408–15.
 9. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of 
endothelial vasomotor function has a negative impact on outcome 
in patients with coronary artery disease. J Am Coll Cardiol 
2009;53:323–30.
 10. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible 
endothelial dysfunction in hypertensive postmenopausal women. J 
Am Coll Cardiol 2002;40:505–10.
 11. Lavi S, Bae JH, Rihal CS, et al. Segmental coronary endothelial 
dysfunction in patients with minimal atherosclerosis is associated 
with necrotic core plaques. Heart 2009;95:1525–30.
 12. Raichlin E, Prasad A, Mathew V, et al. Efficacy and safety 
of atrasentan in patients with cardiovascular risk and early 
atherosclerosis. Hypertension 2008;52:522–8.
 13. Reriani M, Raichlin E, Prasad A, et al. Long-term administration 
of endothelin receptor antagonist improves coronary endothelial 
function in patients with early atherosclerosis. Circulation 
2010;122:958–66.
 14. Rubinshtein R, Yang EH, Rihal CS, et al. Coronary microcirculatory 
vasodilator function in relation to risk factors among patients without 
obstructive coronary disease and low to intermediate Framingham 
score. Eur Heart J 2010;31:936–42.
 15. Reriani MK, Lerman LO, Lerman A. Endothelial function as a 
functional expression of cardiovascular risk factors. Biomark Med 
2010;4:351–60.
 16. Hori M, Kitakaze M, Adenosine KM. Adenosine, the heart, and 
coronary circulation. Hypertension 1991;18:565–74.
 17. Lerman A, Holmes DR, Bell MR, et al. Endothelin in coronary 
endothelial dysfunction and early atherosclerosis in humans. 
Circulation 1995;92:2426–31.
 18. Harrison DG, Bates JN. The nitrovasodilators. new ideas about old 
drugs. Circulation 1993;87:1461–7.
 19. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler 
guide wire for intravascular measurement of coronary artery flow 
velocity. Circulation 1992;85:1899–911.
 20. Ofili EO, Labovitz AJ, Kern MJ. Coronary flow velocity dynamics in 
normal and diseased arteries. Am J Cardiol 1993;71:D3–9.
 21. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary 
vascular endothelial dysfunction. Circulation 2002;106:653–8.
 22. Ware JE, Sherbourne CD. The mos 36-item short-form health Survey 
(SF-36). I. conceptual framework and item selection. Med Care 
1992;30:473–83.
 23. Hays RD, Sherbourne CD, Mazel RM. The rand 36-item health 
survey 1.0. Health Econ 1993;2:217–27.
 24. McHorney CA, Ware JE, Lu JF, et al. The mos 36-item short-
form health Survey (SF-36): III. Tests of data quality, scaling 
assumptions, and reliability across diverse patient groups. Med Care 
1994;32:40–66.
 25. McHorney CA, Ware JE, Raczek AE. The mos 36-Item short-form 
health survey (SF-36): II. psychometric and clinical tests of validity 
in measuring physical and mental health constructs. Med Care 
1993;31:247–63.
 26. Kemp HG, Kronmal RA, Vlietstra RE, et al. Seven year survival of 
patients with normal or near normal coronary arteriograms: a CASS 
registry study. J Am Coll Cardiol 1986;7:479–83.
 27. Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical 
characteristics and left ventricular function. Long-term follow-up 
study. J Am Coll Cardiol 1995;25:807–14.
 28. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary 
microvascular dysfunction is highly prevalent in women with chest 
pain in the absence of coronary artery disease: results from the 
NHLBI wise study. Am Heart J 2001;141:735–41.
Zuerich. Protected by copyright.
 o
n
 21 August 2019 at UZH Hauptbibliothek / Zentralbibliothek
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000870 on 2 February 2019. Downloaded from
 
9Reriani M, et al. Open Heart 2019;6:e000870. doi:10.1136/openhrt-2018-000870
Coronary artery disease
 29. Merz NB, Johnson BD, Kelsey PSF, et al. Diagnostic, prognostic, and 
cost assessment of coronary artery disease in women. Am J Manag 
Care 2001;7:959–65.
 30. Shaw LJ, Merz CN, Pepine CJ, et al. The economic burden of angina 
in women with suspected ischemic heart disease: results from the 
national institutes of health--national heart, lung, and blood institute–
sponsored women's ischemia syndrome evaluation. Circulation 
2006;114:894–904.
 31. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in 
patients with chest pain despite normal coronary angiograms. N Engl 
J Med 1994;330:1411–7.
 32. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory 
enlargement of human atherosclerotic coronary arteries. N Engl J 
Med 1987;316:1371–5.
 33. Schoenhagen P, Nissen SE, Tuzcu EM. Coronary arterial remodeling: 
from bench to bedside. Curr Atheroscler Rep 2003;5:150–4.
 34. Cannon RO, Camici PG, Epstein SE. Pathophysiological dilemma of 
syndrome X. Circulation 1992;85:883–92.
 35. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial 
perfusion in cardiac syndrome X detected by cardiovascular 
magnetic resonance imaging. N Engl J Med 2002;346:1948–53.
 36. Quyyumi AA, Cannon RO, Panza JA, et al. Endothelial dysfunction 
in patients with chest pain and normal coronary arteries. Circulation 
1992;86:1864–71.
 37. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary 
arteries: a changing philosophy. JAMA 2005;293:477–84.
 38. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women 
with myocardial ischemia in the absence of obstructive coronary 
disease: results from the National Institutes of Health-National heart, 
lung, and blood Institute-Sponsored women's ischemia syndrome 
evaluation (wise). Circulation 2004;109:2993–9.
 39. von Mering GO, Arant CB, Wessel TR, et al. Abnormal coronary 
vasomotion as a prognostic indicator of cardiovascular events in 
women: results from the National Heart, lung, and blood institute-
sponsored women's ischemia syndrome evaluation (wise). 
Circulation 2004;109:722–5.
 40. Summers MR, Lerman A, Lennon RJ, et al. Myocardial ischaemia in 
patients with coronary endothelial dysfunction: insights from body 
surface ECG mapping and implications for invasive evaluation of 
chronic chest pain. Eur Heart J 2011;32:2758–65.
 41. Olson MB, Kelsey SF, Matthews K, et al. Symptoms, myocardial 
ischaemia and quality of life in women: results from the NHLBI-
sponsored wise study. Eur Heart J 2003;24:1506–14.
 42. Karlson BW, Wiklund I, Bengtson A, et al. Prognosis, severity of 
symptoms, and aspects of well-being among patients in whom 
myocardial infarction was ruled out. Clin Cardiol 1994;17:427–31.
 43. Perers E, From Attebring M, Caidahl K, et al. Low risk is associated 
with poorer quality of life than high risk following acute coronary 
syndrome. Coron Artery Dis 2006;17:501–10.
 44. Buser MA, Buser PT, Kuster GM, et al. Improvements in physical 
and mental domains of quality of life by anti-ischaemic drug and 
revascularisation treatment in elderly men and women with chronic 
angina. Heart 2008;94:1413–8.
 45. Mattera JA, De Leon CM, Wackers FJ, et al. Association of patients' 
perception of health status and exercise electrocardiogram, 
myocardial perfusion imaging, and ventricular function measures. 
Am Heart J 2000;140:409–18.
 46. Kemp HG, Elliott WC, Gorlin R. The anginal syndrome with normal 
coronary arteriography. Trans Assoc Am Physicians 1967;80:59–70.
 47. Likoff W, Segal BL, Kasparian H. Paradox of normal selective 
coronary arteriograms in patients considered to have unmistakable 
coronary heart disease. N Engl J Med 1967;276:1063–6.
Zuerich. Protected by copyright.
 o
n
 21 August 2019 at UZH Hauptbibliothek / Zentralbibliothek
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000870 on 2 February 2019. Downloaded from
 
